Renalytix uses cookies to improve your experience. We respect your privacy and are committed to protecting your personal data. Read Privacy Notice.
Investors KidneyIntelX

About renalytixprod

This author has not yet filled in any details.
So far renalytixprod has created 112 blog entries.

Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States

Award for consortium of industry, academic and clinical research leaders to develop personalized drug response tests in chronic kidney disease LONDON and SALT LAKE CITY, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces the launch of PRIME-CKD*, a consortium of


Read More
By |2024-06-21T13:26:26+00:0001.26.23|News|0 Comments

Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systems

Significant milestone will make KidneyIntelX accessible to 960,000 veterans with chronic kidney disease LONDON and SALT LAKE CITY, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the execution of a Co-operative Research and Development Agreement (CRADA)


Read More
By |2024-06-21T13:26:26+00:0001.09.23|News|0 Comments

Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease

Risk scoring by KidneyIntelX resulted in a 4.5-fold increase in new drug prescriptions (for SGLT2 inhibitors) for high risk compared to low risk patients, an observed reduction of HbA1c levels in the highest risk patients, an overall increased use of antihypertensive therapeutics, and an observed


Read More
By |2024-06-21T13:26:27+00:0011.29.22|News|0 Comments
Go to Top